AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth

  title={AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth},
  author={Ita Novita Sari and Ying-Gui Yang and Yoseph Toni Wijaya and Nayoung Jun and Sanghyun Lee and Kwang Seock Kim and Jeevisha Bajaj and V. G. Oehler and Soo-hyun Kim and Soo Young Choi and Sahee Park and Dong-Wook Kim and Tannishtha Reya and Jaeseok Han and Hyog Young Kwon},
Polyamines are critical elements in mammals, but it remains unknown whether adenosyl methionine decarboxylase (AMD1), a rate-limiting enzyme in polyamine synthesis, is required for myeloid leukemia. Here, we found that leukemic stem cells (LSCs) were highly differentiated, and leukemia progression was severely impaired in the absence of AMD1 in vivo. AMD1 was highly upregulated as chronic myeloid leukemia (CML) progressed from the chronic phase to the blast crisis phase, and was associated with… 
Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies
Targeting amino acid metabolism provides a host of potential translational opportunities for exploitation to improve the outcomes for patients with myeloid malignancies.


Regulation of myeloid leukemia by the cell fate determinant Musashi
The data show that the Musashi–Numb pathway can control the differentiation of CML cells, and raise the possibility that targeting this pathway may provide a new strategy for the therapy of aggressive leukaemias.
Gene expression changes associated with progression and response in chronic myeloid leukemia.
  • J. RadichH. Dai P. Linsley
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2006
A comparison of the gene signatures of chronic, accelerated, and blast phases suggest that the progression of chronic phase CML to advanced phase (accelerated and blast crisis) CML is a two-step rather than a three-step process, with new gene expression changes occurring early in accelerated phase before the accumulation of increased numbers of leukemia blast cells.
Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma
Efforts to augment DFMO activity, or otherwise maximally reduce polyamine levels, are focused on antagonizing polyamine uptake or augmenting polyamine export or catabolism, particularly when combined with chemotherapy, have great potential for improving neuroblastoma outcome.
Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells
SYNCRIP is identified as a new RBP that controls the myeloid leukemia stem cell program and it is proposed that targeting these RBP complexes might provide a novel therapeutic strategy in leukemia.
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours
SAM486A (CGP 48664) is a new inhibitor of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), more potent and specific than the first-generation SAMDC inhibitor methylglyoxal (bis) guanylhydrazone (MGBG).
Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia
It is shown that the dynein-binding protein Lis1 is critically required for hematopoietic stem cell function and leukemogenesis, and deletion of Lis1 blocked the propagation of myeloid leukemia and led to a marked improvement in survival.
The mechanisms by which polyamines accelerate tumor spread
  • K. Soda
  • Biology
    Journal of experimental & clinical cancer research : CR
  • 2011
Investigations revealed that increased polyamine availability enhances the capability of cancer cells to invade and metastasize to new tissues while diminishing immune cells' anti-tumor immune functions.
Polyamine synthesis enzyme AMD1 is closely associated with tumorigenesis and prognosis of human gastric cancers.
The studies at the cellular, animal and human levels indicate that AMD1 has a tumorigenic effect on human gastric cancers and affect the prognosis of the patients.